MedTrace Logo

Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients

NCT04686760 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 278

Last updated 2022-05-18

No results posted yet for this study

Summary

In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization

Conditions

  • Corona Virus Infection

Interventions

DRUG

Nitroglycerin

2 mg/ml solution of nitroglycerin used for nebulization four hourly

Sponsors & Collaborators

  • University of Lahore

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-15
Primary Completion
2021-12-15
Completion
2022-03-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04686760 on ClinicalTrials.gov